The vaccine was utilized by the World Health Organization and Democratic Republic of the Congo as an investigational vaccine to help reduce Ebola virus disease (EVD) outbreaks in couple of West African countries from 2014 to 2016.
The Ebola virus, which causes haemorrhagic fever and spreads from person to individual through direct contact with body fluids, has killed more than 2,100 individuals in Congo considering that the middle of the year, making it the second-largest Ebola outbreak in history.
The vaccine, which is administered as a single-dose injection, will help to prevent EVD brought on by Zaire ebolavirus in patients aged 18 years and older, the regulator stated in a statement.
In November, Merck received approval from the European Commission to market Ervebo, less than a month after a European medicines panel backed the first-ever vaccine versus the virus.
Merck did not right away react to an ask for remark, after market hours.